Triple

T16946182
Position Surface form Disambiguated ID Type / Status
Subject Sovaldi E411074 entity
Predicate hasGenericName P23148 FINISHED
Object sofosbuvir
Sofosbuvir is a direct-acting antiviral medication used to treat chronic hepatitis C virus infection, often as part of combination therapy.
 E411074 NE FINISHED

How this triple was built (4 steps)

Every LLM step that produced this triple, in pipeline order — named-entity classification, the disambiguation choices (the exact options shown, with the pick highlighted), and the generated description. The batch + timestamp of each is in the Provenance table below.

NER Named-entity recognition gpt-5-mini
Instruction
Given a phrase, classify it is english named entity (e.g., persons, organizations, works of art) in Latin script, or not (e.g., literals, dates, URLs, verbose phrases). For disambiguation, the statement where the phrase occurs as object is also given. Please return a JSON object with `phrase` (string, the phrase being analyzed) and `is_ne` (boolean, indicating whether the phrase is a Named Entity).
Input
Phrase: sofosbuvir | Statement: [Sovaldi, hasGenericName, sofosbuvir]
NED1 Entity disambiguation (via context triple) gpt-5-mini-2025-08-07 
Target entity: sofosbuvir
Context triple: [Sovaldi, hasGenericName, sofosbuvir]
  • A. Sovaldi
    Sovaldi is a breakthrough antiviral medication used to treat chronic hepatitis C by directly inhibiting the virus’s replication.
  • B. Harvoni
    Harvoni is a prescription antiviral medication used to treat chronic hepatitis C virus (HCV) infection.
  • C. Epclusa
    Epclusa is a prescription antiviral medication used to treat chronic hepatitis C infection across all major genotypes.
  • D. Waylivra
    Waylivra is a prescription antisense oligonucleotide therapy used to treat familial chylomicronemia syndrome (FCS) by reducing triglyceride levels in the blood.
  • E. velpatasvir
    Velpatasvir is a direct-acting antiviral medication used in combination with sofosbuvir to treat chronic hepatitis C virus infection across multiple genotypes.
  • F. None of above. chosen
  • G. Unsure - the case is ambiguous/there is not enough information to decide.
NEDg Description generation gpt-5.1
Instruction
Generate a one-sentence description of the target entity. 
You are given a context triple in the form (subject, predicate, object), where the object is the target entity. 
# Instructions
Use the triple to infer relevant information about the entity. Describe the entity based on what is most defining, well-known. 
Avoid repeating the information from the triple, unless really essential.
# Response Format
Return only the sentence: "Description: [one-sentence description of the target entity]"
Input
Entity: sofosbuvir
Triple: [Sovaldi, hasGenericName, sofosbuvir]
Generated description
Sofosbuvir is a direct-acting antiviral medication used to treat chronic hepatitis C virus infection, often as part of combination therapy.
NED2 Entity disambiguation (via description) gpt-5-mini-2025-08-07 
Target entity: sofosbuvir
Target entity description: Sofosbuvir is a direct-acting antiviral medication used to treat chronic hepatitis C virus infection, often as part of combination therapy.
  • A. Sovaldi chosen
    Sovaldi is a breakthrough antiviral medication used to treat chronic hepatitis C by directly inhibiting the virus’s replication.
  • B. Harvoni
    Harvoni is a prescription antiviral medication used to treat chronic hepatitis C virus (HCV) infection.
  • C. Epclusa
    Epclusa is a prescription antiviral medication used to treat chronic hepatitis C infection across all major genotypes.
  • D. Waylivra
    Waylivra is a prescription antisense oligonucleotide therapy used to treat familial chylomicronemia syndrome (FCS) by reducing triglyceride levels in the blood.
  • E. velpatasvir
    Velpatasvir is a direct-acting antiviral medication used in combination with sofosbuvir to treat chronic hepatitis C virus infection across multiple genotypes.
  • F. None of above.

Provenance (5 batches)

The batch behind each pipeline step, in order, with when it ran. Timestamps are batch-level — stages were processed in waves, so the object chain (NER → NED1 → NEDg → NED2) reads in order, but predicate / elicitation batches can sit in a different wave.

Step Stage Batch ID Status When
creating Elicitation batch_69d886c886688190967be07322597ac9 completed April 10, 2026, 5:12 a.m.
NER Named-entity recognition batch_69e3cfb25e0c8190948e62d9575ae9cd completed April 18, 2026, 6:38 p.m.
NED1 Entity disambiguation (via context triple) batch_6a00cfeca4208190a3b9270869063d3d completed May 10, 2026, 6:35 p.m.
NEDg Description generation batch_6a00d0b13f1c819091f3f8b966e36214 completed May 10, 2026, 6:38 p.m.
NED2 Entity disambiguation (via description) batch_6a00d1ad6b7081908be76d70ad9e2075 completed May 10, 2026, 6:42 p.m.
Created at: April 10, 2026, 5:31 a.m.